普瑞巴林联合芬太尼透皮贴在晚期头颈部鳞癌疼痛患者中的疗效分析被引量：1

THERAPEUTIC EFFICACY OF PREGABALIN COMBINED WITH TRANSDERMAL FENTANYL FOR TREATMENT OF PAIN CAUSED BY ADVANCED SQUAMOUS CELL CARCINOMA OF HEAD AND NECK

原文传递

导出

摘要目的探讨普瑞巴林联合芬太尼透皮贴治疗晚期头颈部鳞癌疼痛的临床疗效。方法选择晚期头颈部鳞癌疼痛患者32例,随机分为芬太尼透皮贴单药治疗组(对照组)与普瑞巴林联合芬太尼透皮贴治疗组(联合组)。对照组患者根据疼痛控制情况调整芬太尼透皮贴用量至NRS评分≤3分;联合组在使用芬太尼透皮贴的基础上加用普瑞巴林口服,150mg,2次/d。评价二组患者用药前、用药后1周、2周、4周及8周时的NRS评分、芬太尼使用情况及不良反应发生情况。结果治疗后联合组NRS评分下降更明显(P<0.05);联合组芬太尼透皮贴使用量较对照组明显减少(P<0.05),且不良反应发生率更低。结论普瑞巴林联合芬太尼透皮贴治疗晚期头颈部鳞癌疼痛较单药应用芬太尼透皮贴止疼疗效好,安全性高,不良反应发生较少。 Objective To investigate the effect of pregabalin combined with transdermal fentanyl in the treatment of pain caused by dvanced squamous cell carcinoma of head and neck（SCCHN）. Methods A total of 32 patients with advanced SCCHN were randomly divided into two groups. Sixteen cases in the control group received transdermal fentanyl only, the dosages were gradually adjusted until the numerical rating scales （NRS） ≤3; and other cases in the combined group, pregabalin was coadministered with transdermal fentanyl, similar to the control group, 15.0 mg of pregabalin was administered twice a day. NRS, dosages of transdermal fentanyl and side effects were evaluated before treatment and at one, two, four and eight weeks after the treatment, respectively. Results After treatment,the average NRS decreased more significant in the combined group than that in the control group （P〈0.05）. The dosage＇ of transdermal fentanyl and the side effects in the combined group were less than those in the control group（P〈0.05）. Conclusion Pregabalin combined with transdermal fentanyl is effective for the treatment of pain caused by ad- vanced SCCHN with less adverse reaction.

作者贾佳王莉

机构地区陆军总医院肿瘤科

出处《中国煤炭工业医学杂志》 2017年第5期550-552,共3页 Chinese Journal of Coal Industry Medicine

基金全军医药卫生十一五科技攻关项目(编号:200606M076)

关键词普瑞巴林芬太尼透皮贴晚期头颈部鳞癌 Pregabalin Transdermal fentanyl Advanced SCCHN

分类号 R739.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献1

1司马蕾,厉建春,蔡淑呈,水源,樊碧发.118例神经病理性癌痛临床特点与治疗[J].中国癌症杂志,2011,21(11):898-900. 被引量：9

二级参考文献15

1BENNETT M I,SMITH B H,TORRANCE N,et al:The S-LANSS score for identifying pain of predominantly neuropathic origin:Validation for use in clinic and postal research[J].J Pain,2005,6(3):149-158.
2BOUHASSIRA D,ATTAL N,ALCHAAR H.Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)[J].Pain,2005,114(1-2):29-36.
3GIBBY C R,MORROW P K,BENNETT M I,et al.Neuropathic pain in breast cancer survivors:Using the ID Pain as a screening tool[J].J Pain Symptom Manag,2010,39(5):882-889.
4CARVER A,FOLEY K.Facts and an open mind should guide clinical practice[J].Curr Neurol Neurosci Rep,2001,1(2):97-98.
5MERCADANTE S,PORTENOY R K.Opioid poorlyresponsive cancer pain.Part 3.Clinical strategies to improve opioid responsiveness[J].J Pain Symptom Manage,2001,21(4):338-354.
6RAJA S N,HAYTHORNTHWAITE J A,PAPPAGALLO M,et al.Opioids versus antidepressants in post herpetic neuralgia:a randomized,placebo-controlled trial[J].Neurology,2002,59(7):1015-1021.
7EISENBERG E,MCNICOL E D,CARR D B.Efficacy and safety opioid agonists in the treatment of neuropathic pain of nonmalignant origin:system review and meta-analysis of randomized controlled trials[J].JAMA,2005,293(24):3043-3052.
8RAJAS N,Haythornthwaite J A.Combination therapy for neuropathic pain-which drugs,which combination,which patients?[J].N Engl J Med,2005,352(13):13.
9FOLEY K M.Opioids and chronic neuropathic pain[J].N Engl J Med,2003,348(13):1279-1281.
10ROOSDE,O'BRIEN PC,SMITH JG,et al.Arolefor radiotherapy in neuropathic bone pain:preliminary response rates from a prospective trial (Trans-tasman Radiation Oncology Group,TROG 96.05)[J].Int J Radiat Oncol BiolPhys,2000,46(4):975-981.